337 related articles for article (PubMed ID: 27646943)
1. Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors.
Bagrodia A; Lee BH; Lee W; Cha EK; Sfakianos JP; Iyer G; Pietzak EJ; Gao SP; Zabor EC; Ostrovnaya I; Kaffenberger SD; Syed A; Arcila ME; Chaganti RS; Kundra R; Eng J; Hreiki J; Vacic V; Arora K; Oschwald DM; Berger MF; Bajorin DF; Bains MS; Schultz N; Reuter VE; Sheinfeld J; Bosl GJ; Al-Ahmadie HA; Solit DB; Feldman DR
J Clin Oncol; 2016 Nov; 34(33):4000-4007. PubMed ID: 27646943
[TBL] [Abstract][Full Text] [Related]
2. The Role of
Timmerman DM; Eleveld TF; Gillis AJM; Friedrichs CC; Hillenius S; Remmers TL; Sriram S; Looijenga LHJ
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769213
[TBL] [Abstract][Full Text] [Related]
3. Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.
Feldman DR; Iyer G; Van Alstine L; Patil S; Al-Ahmadie H; Reuter VE; Bosl GJ; Chaganti RS; Solit DB
Clin Cancer Res; 2014 Jul; 20(14):3712-20. PubMed ID: 24812411
[TBL] [Abstract][Full Text] [Related]
4. Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors.
Timmerman DM; Eleveld TF; Sriram S; Dorssers LCJ; Gillis AJM; Schmidtova S; Kalavska K; van de Werken HJG; Oing C; Honecker F; Mego M; Looijenga LHJ
J Clin Oncol; 2022 Sep; 40(26):3077-3087. PubMed ID: 35442716
[TBL] [Abstract][Full Text] [Related]
5. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation.
Houldsworth J; Xiao H; Murty VV; Chen W; Ray B; Reuter VE; Bosl GJ; Chaganti RS
Oncogene; 1998 May; 16(18):2345-9. PubMed ID: 9620551
[TBL] [Abstract][Full Text] [Related]
6. Genomic evolution and chemoresistance in germ-cell tumours.
Taylor-Weiner A; Zack T; O'Donnell E; Guerriero JL; Bernard B; Reddy A; Han GC; AlDubayan S; Amin-Mansour A; Schumacher SE; Litchfield K; Turnbull C; Gabriel S; Beroukhim R; Getz G; Carter SL; Hirsch MS; Letai A; Sweeney C; Van Allen EM
Nature; 2016 Nov; 540(7631):114-118. PubMed ID: 27905446
[TBL] [Abstract][Full Text] [Related]
7. The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something?
Ottaviano M; Giunta EF; Rescigno P; Pereira Mestre R; Marandino L; Tortora M; Riccio V; Parola S; Casula M; Paliogiannis P; Cossu A; Vogl UM; Bosso D; Rosanova M; Mazzola B; Daniele B; Palmieri G; Palmieri G
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281219
[TBL] [Abstract][Full Text] [Related]
8. Biological markers of cisplatin resistance in advanced testicular germ cell tumours.
García-Velasco A; Durán I; García E; Tarón M; Ballestín C; Castellanos D; Cortés-Funés H; Paz-Ares L
Clin Transl Oncol; 2012 Jun; 14(6):452-7. PubMed ID: 22634534
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors.
Honecker F; Wermann H; Mayer F; Gillis AJ; Stoop H; van Gurp RJ; Oechsle K; Steyerberg E; Hartmann JT; Dinjens WN; Oosterhuis JW; Bokemeyer C; Looijenga LH
J Clin Oncol; 2009 May; 27(13):2129-36. PubMed ID: 19289622
[TBL] [Abstract][Full Text] [Related]
10. Role of N-cadherin in proliferation, migration, and invasion of germ cell tumours.
Bremmer F; Schallenberg S; Jarry H; Küffer S; Kaulfuss S; Burfeind P; Strauß A; Thelen P; Radzun HJ; Ströbel P; Honecker F; Behnes CL
Oncotarget; 2015 Oct; 6(32):33426-37. PubMed ID: 26451610
[TBL] [Abstract][Full Text] [Related]
11. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours.
Cierna Z; Miskovska V; Roska J; Jurkovicova D; Pulzova LB; Sestakova Z; Hurbanova L; Machalekova K; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Kajo K; Babal P; Mardiak J; Ward TA; Mego M; Chovanec M
BMC Cancer; 2020 Jan; 20(1):17. PubMed ID: 31906898
[TBL] [Abstract][Full Text] [Related]
12. New insights into germ cell tumor genomics.
Lafin JT; Bagrodia A; Woldu S; Amatruda JF
Andrology; 2019 Jul; 7(4):507-515. PubMed ID: 30896089
[TBL] [Abstract][Full Text] [Related]
13. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
[TBL] [Abstract][Full Text] [Related]
14. Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf
Chapeau EA; Gembarska A; Durand EY; Mandon E; Estadieu C; Romanet V; Wiesmann M; Tiedt R; Lehar J; de Weck A; Rad R; Barys L; Jeay S; Ferretti S; Kauffmann A; Sutter E; Grevot A; Moulin P; Murakami M; Sellers WR; Hofmann F; Jensen MR
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3151-3156. PubMed ID: 28265066
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies.
Nishikawa M; Miyake H; Fujisawa M
Int J Clin Oncol; 2016 Feb; 21(1):162-7. PubMed ID: 26123313
[TBL] [Abstract][Full Text] [Related]
16. A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors.
Necchi A; Pond GR; Nicolai N; Giannatempo P; Raggi D; Adra N; Hanna NH; Salvioni R; Einhorn LH; Albany C
Clin Genitourin Cancer; 2017 Apr; 15(2):306-312.e3. PubMed ID: 27594554
[TBL] [Abstract][Full Text] [Related]
17. Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent.
Piulats JM; Vidal A; García-Rodríguez FJ; Muñoz C; Nadal M; Moutinho C; Martínez-Iniesta M; Mora J; Figueras A; Guinó E; Padullés L; Aytés À; Molleví DG; Puertas S; Martínez-Fernández C; Castillo W; Juliachs M; Moreno V; Muñoz P; Stefanovic M; Pujana MA; Condom E; Esteller M; Germà JR; Capella G; Farré L; Morales A; Viñals F; García-Del-Muro X; Cerón J; Villanueva A
Clin Cancer Res; 2018 Aug; 24(15):3755-3766. PubMed ID: 29618620
[No Abstract] [Full Text] [Related]
18. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
[TBL] [Abstract][Full Text] [Related]
19. The component of the m
Miranda-Gonçalves V; Lobo J; Guimarães-Teixeira C; Barros-Silva D; Guimarães R; Cantante M; Braga I; Maurício J; Oing C; Honecker F; Nettersheim D; Looijenga LHJ; Henrique R; Jerónimo C
J Exp Clin Cancer Res; 2021 Aug; 40(1):268. PubMed ID: 34446080
[TBL] [Abstract][Full Text] [Related]
20. Proteomic profiling of cisplatin-resistant and cisplatin-sensitive germ cell tumour cell lines using quantitative mass spectrometry.
Fichtner A; Bohnenberger H; Elakad O; Richter A; Lenz C; Oing C; Ströbel P; Kueffer S; Nettersheim D; Bremmer F
World J Urol; 2022 Feb; 40(2):373-383. PubMed ID: 35084545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
